📊 NVNO Key Takeaways
Is enVVeno Medical Corp (NVNO) a Good Investment?
enVVeno is a pre-commercial medical device startup with unsustainable unit economics: $161K annual revenue against $19.5M net losses and $15.6M annual cash burn. With only $3.1M in cash reserves, the company faces critical funding pressure within months without significant operational changes or capital raise. Positive gross margins indicate product viability, but commercial traction remains nonexistent.
enVVeno remains pre-commercial with minimal revenue and extremely negative margins and free cash flow, indicating an unsustainable operating profile on fundamentals. Despite a debt-free balance sheet and low liabilities, cash appears limited relative to the ~$15.6M annual operating burn, implying reliance on near-term external financing. Until revenue scales materially and gross margins improve, risk to continuity and dilution remains high.
Why Buy enVVeno Medical Corp Stock? NVNO Key Strengths
- Positive gross margin (19.4%) demonstrates underlying product economics are sound
- Zero long-term debt and strong stockholders' equity ($27.1M) provides capital flexibility
- Excellent liquidity position (13.58x current ratio) provides near-term operational cushion
- High percentage revenue growth (747% YoY) suggests nascent commercialization efforts
- Debt-free balance sheet with low liabilities
- Very high current ratio indicating near-term liquidity
- YoY improvement in losses and strong revenue growth off a small base
NVNO Stock Risks: enVVeno Medical Corp Investment Risks
- Critical cash runway: $3.1M cash against $15.6M annual burn rate equals ~2.4 months of operations
- Negligible absolute revenue ($161K) creates revenue-to-loss ratio of 1:121, indicating business model is not yet proven
- Negative operating cash flow and free cash flow indicate company cannot fund operations organically
- Medical device sector requires extended development and regulatory timelines with no visibility to profitability
- High insider selling or stagnant Form 4 activity suggests limited insider confidence
- Severe negative operating cash flow and large operating losses
- Limited cash relative to burn, raising dilution/financing risk
- Early-stage commercialization with low gross margin and execution risk
Key Metrics to Watch
- Cash burn rate and runway to depletion
- Absolute revenue growth in next quarters (percentage growth is misleading from tiny base)
- Operating cash flow trend and pathway to cash flow breakeven
- Capital raise announcements and dilution impact on existing shareholders
- Operating cash flow (burn rate)
- Cash & equivalents (runway)
enVVeno Medical Corp (NVNO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.58x current ratio provides a solid financial cushion.
NVNO Profit Margin, ROE & Profitability Analysis
NVNO vs Healthcare Sector: How enVVeno Medical Corp Compares
How enVVeno Medical Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is enVVeno Medical Corp Stock Overvalued? NVNO Valuation Analysis 2026
Based on fundamental analysis, enVVeno Medical Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
enVVeno Medical Corp Balance Sheet: NVNO Debt, Cash & Liquidity
NVNO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: enVVeno Medical Corp's revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-44.53 indicates the company is currently unprofitable.
NVNO Revenue Growth, EPS Growth & YoY Performance
NVNO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $31.2K | -$1.2M | N/A |
| Q2 2020 | $31.2K | -$1.2M | N/A |
| Q1 2020 | $31.2K | -$1.2M | N/A |
| Q3 2019 | $31.2K | -$1.5M | N/A |
| Q2 2019 | $31.2K | -$1.6M | N/A |
| Q1 2019 | $31.1K | -$1.6M | N/A |
| Q3 2018 | $27.9K | -$1.5M | N/A |
| Q2 2018 | $38.8K | -$1.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
enVVeno Medical Corp Dividends, Buybacks & Capital Allocation
NVNO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for enVVeno Medical Corp (CIK: 0001661053)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NVNO
What is the AI rating for NVNO?
enVVeno Medical Corp (NVNO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NVNO's key strengths?
Claude: Positive gross margin (19.4%) demonstrates underlying product economics are sound. Zero long-term debt and strong stockholders' equity ($27.1M) provides capital flexibility. ChatGPT: Debt-free balance sheet with low liabilities. Very high current ratio indicating near-term liquidity.
What are the risks of investing in NVNO?
Claude: Critical cash runway: $3.1M cash against $15.6M annual burn rate equals ~2.4 months of operations. Negligible absolute revenue ($161K) creates revenue-to-loss ratio of 1:121, indicating business model is not yet proven. ChatGPT: Severe negative operating cash flow and large operating losses. Limited cash relative to burn, raising dilution/financing risk.
What is NVNO's revenue and growth?
enVVeno Medical Corp reported revenue of $161.0K.
Does NVNO pay dividends?
enVVeno Medical Corp does not currently pay dividends.
Where can I find NVNO SEC filings?
Official SEC filings for enVVeno Medical Corp (CIK: 0001661053) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NVNO's EPS?
enVVeno Medical Corp has a diluted EPS of $-33.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NVNO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, enVVeno Medical Corp has a STRONG SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NVNO stock overvalued or undervalued?
Valuation metrics for NVNO: ROE of -71.8% (sector avg: 15%), net margin of -12,094.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NVNO stock in 2026?
Our dual AI analysis gives enVVeno Medical Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NVNO's free cash flow?
enVVeno Medical Corp's operating cash flow is $-15.6M, with capital expenditures of $5.0K. FCF margin is -9,672.7%.
How does NVNO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -12,094.4% (avg: 12%), ROE -71.8% (avg: 15%), current ratio 13.58 (avg: 2).